GlassScriptPhysician profile
Alejandro Alva
NPI 1801816764
$271,012.66
in general payments reported to CMS, 2019-2025
56 companies · $77K in 2025
The $77K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $14K · 2021: $17K · 2022: $29K · 2023: $41K · 2024: $63K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Travel and Lodging: $30K · Food and Beverage: $24K · Consulting Fee: $18K · Honoraria: $7,300 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,730.10 |
| Travel and Lodging | $30,361.61 |
| Food and Beverage | $23,551.95 |
| Consulting Fee | $18,458.00 |
| Honoraria | $7,300.00 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $78,280.04 | 2019-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $65,773.90 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40,166.56 | 2020-2025 | Caplyta |
| H. Lundbeck A S | $26,306.05 | 2023-2024 | Rexulti, Brintellix, Abilify Maintena |
| Neurocrine Biosciences, INC. | $11,269.98 | 2019-2025 | Ingrezza |
| Mdd US Operations, LLC | $10,493.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $7,303.38 | 2019-2022 | |
| Abbvie INC. | $4,217.73 | 2021-2025 | Vraylar, Qulipta |
| Janssen Pharmaceuticals, INC | $3,706.84 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $3,310.51 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Biogen, INC. | $2,576.02 | 2021-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $1,901.40 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $1,731.76 | 2019-2025 | Rexulti, Abilify Maintena |
| Livanova USA, INC. | $1,567.92 | 2020-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Vanda Pharmaceuticals INC. | $1,549.16 | 2019-2025 | Fanapt, Hetlioz |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,089.18 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $884.83 | 2022-2025 | Qelbree, Qelbree |
| Neuronetics, INC. | $858.84 | 2019-2023 | Neurostar Tms Therapy System |
| Uswm, LLC | $851.37 | 2021-2024 | Lucemyra, Zimhi |
| Avanir Pharmaceuticals, INC. | $798.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $798.25 | 2019-2024 | Trintellix |
| Indivior INC. | $742.36 | 2019-2025 | Perseris, Sublocade |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $595.57 | 2019-2025 | Rexulti, Rejoyn |
| Bausch Health US, LLC | $460.70 | 2019-2024 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $400.66 | 2020-2025 | Xelstrym, Secuado |
| Luye Pharma (USA) LTD. | $386.22 | 2025 | Erzofri Extended-Release |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.00 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $336.11 | 2019-2024 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $243.92 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $219.99 | 2023-2025 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $200.33 | 2024-2025 | Cobenfy |
| Brainsway USA INC | $197.38 | 2020 | |
| Braeburn INC. | $186.94 | 2025 | Brixadi |
| Tris Pharma INC | $162.29 | 2021-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Merck Sharp & Dohme LLC | $160.43 | 2020-2023 | Belsomra |
| Adlon Therapeutics L.P. | $151.67 | 2020-2021 | |
| Eisai INC. | $117.61 | 2020-2021 | |
| Corium, LLC | $94.63 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $86.65 | 2019-2023 | Jornay Pm |
| Avadel Cns Pharmaceuticals, LLC | $65.20 | 2025 | Lumryz |
| Lilly USA, LLC | $64.06 | 2020-2025 | Kisunla, Amyvid |
| Boston Scientific Corporation | $46.78 | 2023 | |
| Avion Pharmaceuticals | $43.90 | 2023-2024 | Methylphenidate Hydrochloride |
| Sun Pharmaceutical Industries INC. | $42.71 | 2021 | |
| Jazz Pharmaceuticals INC. | $37.52 | 2021 | |
| Alfasigma USA, INC. | $34.42 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.50 | 2019 | |
| Orexo US, INC. | $22.81 | 2021 | |
| Pfizer INC. | $22.01 | 2019 | |
| Owp Pharmaceuticals, INC. | $21.00 | 2022 | |
| Assertio Therapeutics, INC. | $19.32 | 2019 | |
| Gilead Sciences, INC. | $19.03 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Alva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.